Geneva Capital Management LLC Decreases Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geneva Capital Management LLC lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 904,724 shares of the medical instruments supplier’s stock after selling 1,904 shares during the period. Geneva Capital Management LLC owned about 4.06% of LeMaitre Vascular worth $51,352,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Exchange Traded Concepts LLC boosted its stake in shares of LeMaitre Vascular by 0.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after purchasing an additional 187 shares during the period. Riverwater Partners LLC grew its stake in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 198 shares in the last quarter. Swiss National Bank increased its position in shares of LeMaitre Vascular by 1.2% during the third quarter. Swiss National Bank now owns 43,900 shares of the medical instruments supplier’s stock worth $2,392,000 after acquiring an additional 500 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in shares of LeMaitre Vascular by 325.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 524 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in LeMaitre Vascular by 0.7% in the third quarter. Victory Capital Management Inc. now owns 76,915 shares of the medical instruments supplier’s stock valued at $4,190,000 after purchasing an additional 557 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares of the company’s stock, valued at approximately $148,817,393.78. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total value of $5,216,184.20. Following the completion of the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The disclosure for this sale can be found here. Insiders sold 195,967 shares of company stock valued at $14,072,324 over the last 90 days. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Trading Up 1.3 %

NASDAQ:LMAT traded up $1.00 during mid-day trading on Thursday, hitting $76.00. The stock had a trading volume of 127,948 shares, compared to its average volume of 122,788. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $76.24. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 50.33, a P/E/G ratio of 2.99 and a beta of 0.88. The company has a 50 day simple moving average of $66.67 and a 200-day simple moving average of $59.46.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. During the same period in the previous year, the firm posted $0.27 earnings per share. The business’s revenue was up 13.6% on a year-over-year basis. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent analyst reports. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp started coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They issued a “sector weight” rating for the company. Barrington Research upped their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Finally, JMP Securities raised their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $73.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.